Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
Cancer Lett. 2013 Oct 1;339(1):42-8. doi: 10.1016/j.canlet.2013.07.024. Epub 2013 Jul 26.
This study aims to determine the effect of metronomic (0.0125 mg/kg twice a week for 4 weeks) zoledronic acid (ZOL) on cancer propagation and osteolysis against both metastatic and primary breast cancer in mice model. From our results, metronomic ZOL resulted in a significant reduction of tumor burden and did not promote lung or liver metastasis. The metronomic ZOL appeared to be more effective than the conventional regimen (0.1 mg/kg once in 4 weeks) in reducing breast cancer tumor burden, and regulating its movement to lung and liver. This dosing schedule of ZOL showed great potential against metastatic breast cancer.
本研究旨在确定节拍式（每周两次，每次 0.0125 毫克/千克，共 4 周）唑来膦酸（ZOL）对小鼠模型中转移性和原发性乳腺癌的肿瘤增殖和溶骨性的影响。我们的结果表明，节拍式 ZOL 可显著降低肿瘤负担，并且不会促进肺或肝转移。与常规方案（每 4 周 0.1 毫克/千克一次）相比，节拍式 ZOL 似乎更有效地降低乳腺癌肿瘤负担，并调节其向肺和肝的转移。ZOL 的这种给药方案对转移性乳腺癌具有很大的潜力。
